Genetic Signatures Ltd. · ASX:GSS
Genetic Signatures — 6th Annual Australian Microcap Investment Conference 2015
29 slides from Genetic Signatures's conference presentation, Oct 20, 2015
Slide 1: Genetic Signatures CEO to present at Australian Microcap Investment Conference
20 October 2015 Markets Announcements Office ASX Limited Exchange Centre 20 Bridge Street SYDNEY NSW 2000 For personal use only Genetic Signatures CEO to present at the 6th Annual Australian Microcap Investment Conference The largest conference in Australia focussed on emerging companies Present
Slide 2: About the conference and Genetic Signatures
largest conference in Australia focussed on emerging companies and regularly attracts over 300 delegates from Australia and internationally. About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of it
Slide 3: 2015 Microcap Conference
For personal use only 2015 Microcap Conference 1
Slide 4: Disclaimer
Disclaimer For personal use only This presentation was prepared by Genetic Signatures Limited known as “Genetic Signatures“, (“GSS” or “the Company”), in order to discuss its business with various interested parties. This presentation in its entirety has been released to the market via the Australia
Slide 5: Transforming Molecular Diagnostics
Transforming Molecular Diagnostics For personal use only Genetic Signatures is a molecular diagnostics (MDx) company operating in the global IVD (in vitro diagnostics) industry with new technology in infection control. Our primary focus is the development and supply of world leading diagnostic solut
Slide 6: Corporate Summary
Corporate Summary For personal use only Capital Structure ASX Code GSS Shares on Issue 72.9m Market Capitalisation $34m Share Price (at market close 16 October, 2015) $0.465 Cash at June 30 $5.46m Directors & Chief Executive Nick Samaras Non-Executive Chairman John Melki Director & CEO Mike Aicher E
Slide 7: Board and Management
Board and Management For personal use only Nick Samaras - Non-Executive Chairman BSc (Hons), PhD, MBA, FAIM, FAICD § More than 25 years’ experience in the global life sciences industry, senior executive roles with Applied Biosystems and Perkin Elmer § NHMRC Research Committee member 2006-12, Adjunct
Slide 8: Board and Management
Board and Management For personal use only Tony Radford- Non-Executive Director BSc (Hons), PhD § Former CEO of Cellestis from founding until its acquisition by QIAGEN NV in 2011 for approximately $400 million § Previous Head of Development in 2000 at AMRAD in pharmaceutical research § a member of t
Slide 9: Company Overview
Company Overview For personal use only § Genetic Signatures provides diagnostic solutions for rapid pathogen detection § Proprietary technology driving product development for pathology and hospital customers globally in multiple markets, with IP protection to 2031 § Products already available in Au
Slide 10: Technology - 3Base
Technology - 3Base™ For personal use only Platform technology converts original 4-base microbial genome to 3-base, thereby reducing complexity in molecular testing. Applicable in testing for infectious diseases and chronic diseases including cancers 8
Slide 11: Technology - 3Base
Technology - 3Base™ For personal use only § 3Base™ improves subtype similarity and reduces variation, allowing easier PCR design § e.g, a 10 digit number comprised of the numbers 1,2,3 and 4 has 1,048,576 combinations § a 10 digit number comprised of the numbers 1,2 and 3 has 59,049 combinations § S
Slide 12: Technology - 3Base
Technology - 3Base™ For personal use only A transformational MDx technology enabling customers to identify a wider array of patient infections § Genetic Signatures’ 3Base™ platform is a proprietary molecular technique which changes naturally occurring DNA and RNA sequences to reduce sequence variati
Slide 13: Targeting Critical Health
Targeting Critical Health For personal use only § Gastroenteritis is a major widespread clinical problem (16.8 million cases per annum in Australia alone) resulting in 250,000 visits to hospital emergency departments, 15,000 hospitalisations and 80 deaths) § Genetic Signatures’ gastroenteritis testi
Slide 14: Genetic Signatures: Transforming Global Molecular Diagnostics
For personal use only Genetic Signatures Transforming Global Molecular Diagnostics 12
Slide 15: EasyScreen Testing Kits
EasyScreen™ Testing Kits For personal use only § GSS’ suite of EasyScreen™ products are used by major hospitals in Australia for detection of infectious diseases – 55,000 tests were sold and used in FY15 § Products work with existing customer systems to deliver a wider array of highly specific resul
Slide 16: Case Study: St Vincent's Hospital Evaluation Study
Case Study: St Vincent’s Hospital Evaluation Study - EasyScreen™ vs. Traditional Methods For personal use only Pathogen Conventional EasyScreen™ METHODS: Methods* § Primary focus of study was to assess Campylobacter 7 9 the clinical utility of EasyScreen™ in Salmonella 8 9 detecting infectious agent
Slide 17: Customer testimonial
For personal use only “I find that the fast turnaround time and the number of targets tested in the EasyScreen™ assays allow me to more rapidly identify highly infectious agents, potentially stopping the spread to other healthy individuals and thereby saving the health system money.” - Dr Damien Sta
Slide 18: EasyScreen Product Development Pathway
EasyScreen™ Product Development Pathway For personal use only Each product goes through extensive development and beta testing and adheres to rigorous quality management systems & regulatory approach. § ISO9001 and ISO13485 certified § Already approved by Australian and European regulators 16
Slide 19: Competitive Advantage
Competitive Advantage For personal use only § GSS is unique in supplying products that screen over 20 pathogens, including RNA and DNA viruses, in a probe based real-time format § Uses latest technology compatible with existing equipment (open platform) § Ease of use and automation § Rapid time to r
Slide 20: Global Growth Strategy
For personal use only Global Growth Strategy 18
Slide 21: 2015 Highlights
2015 Highlights For personal use only Financial Growth § Completed oversubscribed Initial Public Offering (IPO) to raise $7.5 million and list on the Australian Securities Exchange (ASX) § Achieved greater than $1 million in annual sales revenue for the first time in the history of the Company § Dia
Slide 22: 2015 Financial Results
2015 Financial Results For personal use only 30 June 2015 30 June 2014 % Increase $ $ (decrease) Revenue from 1,043,269 684,277 52.5% continuing operations Net loss from (2,659,120) (1,728,487) (53.8)% ordinary activities after tax attributable to shareholders Net loss for the (2,659,120) (1,728,487
Slide 23: FY15 Results Overview
FY15 Results Overview For personal use only § A number of significant non-recurring costs were paid in FY2015 and will not have any further impact on cash flow, including $515,000 related to the Company’s IPO and $165,000 for capital equipment required to increase product development throughput in t
Slide 24: 2015 Operational Highlights
2015 Operational Highlights For personal use only Global Market Reach Expansion § US subsidiary, Genetic Signatures US Ltd incorporated and its US team expanded § Established first European sales channel partnerships with distributors for the regions of Italy and Israel Product Range Expansion § Mov
Slide 25: Commercialisation Progress - Australia
Commercialisation Progress - Australia For personal use only • Currently in market with major hospital and pathology group customers § Testing for 22 causes of gastroenteritis § Testing for 15 causes of viral respiratory disease § Next new product in beta testing with customer § Dr Tony Radford join
Slide 26: Commercialisation Progress - Europe
Commercialisation Progress - Europe For personal use only § Established operations in 2013 § Signed Italian distributor and testing with large pathology laboratories, recurrent revenues commencing § Signed Israeli distributor agreement § Increased European sales channel partnership network by signin
Slide 27: Commercialisation Progress - United States
Commercialisation Progress - United States For personal use only § Established operations in 2014 with appointment of key personnel § In FY15 GSS achieved first regulatory step towards full product suite commercialisation in the US with receipt of a United States Food and Drug Administration (FDA) l
Slide 28: Summary
Summary For personal use only § EasyScreen™ Respiratory & Enteric Pathogen Detection Kits provide faster & more accurate screening for viral, bacterial and protozoan pathogens – tests are processed in hours instead of days, with fewer false positives and negatives § The 3Base™ platform and products
Slide 29: Contact
For personal use only Contact: John Melki Chief Executive Officer john@geneticsignatures.com www.geneticsignatures.com 27
Genetic Signatures — 6th Annual Australian Microcap Investment Conference 2015 on 6ix